First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin

Roberto Iacovelli, Chiara Ciccarese, M. Brunelli, N. Battelli, C. Buttigliero, C. Caserta, S. Buti, D. Santini, C. Carella, L. Galli, E. Verri, P. Ermacora, S. Merler, C. Masini, R. De Vivo, L. Milesi, F. Spina, M. Rizzo, I. Sperduti, G. FornariniGiampaolo Tortora

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Background: Cisplatin-based chemotherapy is the most recommended treatment for metastatic urothelial cancer (mUC). However, about 50% of patients are considered to be cisplatin ineligible. Anti-programmed cell death protein 1/programmed death-ligand 1 (PD-L1) therapies have, nevertheless, increased the options available to clinicians and are especially valuable for treating these patients. This study therefore tested the activity and safety of avelumab as first-line therapy for mUC. Patients and methods: Patients with mUC who were ineligible for cisplatin-based chemotherapy were screened centrally for PD-L1 expression and only those with a tumour proportion score ≥ 5% were enrolled in the trial. The primary endpoint was 1-year overall survival (OS), and the secondary endpoints were median OS, median progression-free survival, overall response rate, duration of the response, safety and tolerability. All the survival rates were estimated with the Kaplan–Meier product-limit methodology and compared across groups using the log-rank test. Results: A total of 198 patients were screened, with 71 (35.9%) whose PD-L1 expression was ≥5% enrolled in the study. The median age was 75 years, bladder cancer was the primary tumour in 73.2% of cases and 25.3% had liver metastases. The main reasons for the cisplatin ineligibility were a low rate of creatinine clearance (<60 ml/min), present in 70.4% of patients, and an Eastern Cooperative Oncology Group performance status of 2, which affected 31%. The median OS was 10.0 months (95% confidence interval 5.5-14.5 months) and 43% of patients were alive at 1 year. A complete response was achieved in 8.5% of cases, and 15.5% had a partial response. Adverse any-grade and high-grade events occurred in 49.3% and 8.5% of patients, respectively. A grade 3 infusion reaction was the only high-grade treatment-related adverse event. No treatment-related deaths were reported. Conclusions: This ARIES trial confirmed the activity and safety of avelumab for treating mUC, adding a new therapy option to the armamentarium of checkpoint inhibitors already approved for platinum-ineligible, locally advanced/mUC.
Lingua originaleEnglish
pagine (da-a)1179-1185
Numero di pagine7
RivistaAnnals of Oncology
Volume33
DOI
Stato di pubblicazionePubblicato - 2022

Keywords

  • avelumab
  • biomarkers
  • PD-L1
  • cisplatin ineligible
  • immunotherapy
  • bladder cancer

Fingerprint

Entra nei temi di ricerca di 'First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin'. Insieme formano una fingerprint unica.

Cita questo